Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Jan 2017

Asada Ayumi, Bamba Shigeki, Morita Yukihiro, Takahashi Kenichiro, Imaeda Hirotsugu, Nishida Atsushi, Inatomi Osamu, Sugimoto Mitsushige, Sasaki Masaya, Andoh Akira

Abstract excerpt

BACKGROUND: Tacrolimus is an immunosuppressive agent, used in the remission induction therapy of ulcerative colitis (UC). AIMS: We investigated the correlation between CYP3A5 genetic polymorphisms and the adverse events in patients with UC. The pharmacokinetics of tacrolimus after oral administration were also analyzed. METHODS: We enrolled 29 hospitalized patients with UC received oral tacrolimus. Genotyping for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Genotype

Share to Immunosuppressive Agents

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Share to Treatment Outcome

Source

Identifiers

PMID: 27717793
DOI: 10.1016/j.dld.2016.09.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.PMID 27717793Read ↗

The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.Semantic proximity Read ↗

CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.Semantic proximity Read ↗

Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.Semantic proximity Read ↗

CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant.Semantic proximity Read ↗

CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients.Semantic proximity Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

Effect of CYP3A5 Gene Polymorphisms on Tacrolimus Blood Concentrations and Adverse Events in Allogeneic Hematopoietic Stem Cell Transplant Patients.Semantic proximity Read ↗

The effects of the CYP3A5*3 variant on tacrolimus pharmacokinetics and outcomes in Tunisian kidney transplant recipients.Semantic proximity Read ↗

CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.Semantic proximity Read ↗

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.